These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 30394056

  • 1. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
    Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA, OPTI‐CLOT study group.
    J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.
    Suzuki A, Tomono Y, Korth-Bradley JM.
    Haemophilia; 2016 Sep; 22(5):e359-66. PubMed ID: 27353956
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y, Roberts J, Bensen-Kennedy D, Jacobs I, Santagostino E, Voigt C, Feussner A, Morfini M, Sidhu J.
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
    Alamelu J, Bevan D, Sorensen B, Rangarajan S.
    J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
    [Abstract] [Full Text] [Related]

  • 7. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Garzone PD, Schaub RG.
    Blood; 1996 Oct 01; 88(7):2603-10. PubMed ID: 8839853
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
    Björkman S.
    Haemophilia; 2013 Sep 01; 19(5):753-7. PubMed ID: 23731351
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E.
    J Thromb Haemost; 2012 Nov 01; 10(11):2305-12. PubMed ID: 22998153
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
    Björkman S.
    Haemophilia; 2013 Nov 01; 19(6):808-13. PubMed ID: 23786333
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM, Rendo P, Smith L, Altisent C.
    Clin Ther; 2016 Apr 01; 38(4):936-44. PubMed ID: 26969334
    [Abstract] [Full Text] [Related]

  • 17. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S.
    Haemophilia; 2013 Nov 01; 19(6):882-6. PubMed ID: 24165155
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
    Björkman S, Shapiro AD, Berntorp E.
    Haemophilia; 2001 Mar 01; 7(2):133-9. PubMed ID: 11260271
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.
    Koopman SF, Goedhart TMHJ, Bukkems LH, Mulders TM, Leebeek FWG, Fijnvandraat K, Coppens M, Mathias M, Collins PW, Tait RC, Bagot CN, Curry N, Payne J, Chowdary P, Cnossen MH, Mathôt RAA, OPTI-CLOT study group and SYMPHONY consortium.
    Br J Clin Pharmacol; 2024 Jan 01; 90(1):220-231. PubMed ID: 37567779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.